| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/28/2005 | US20050090531 MAG expression promoters |
| 04/28/2005 | US20050090524 Novel adamantane derivatives |
| 04/28/2005 | US20050090523 2-(substituted phenyl)imidazo[1,2-a]pyridine compounds; use to treat disorders mediated by the histamine H3 receptor such as sleep disorders, attention deficit hyperactivity disorder, or Alzheimer's disease; 2-[4-[3-(Piperidino)propylamino]phenyl]-8-methylimidazo[1,2-a]pyridine for example |
| 04/28/2005 | US20050090519 1-Alkyl-4-(3-substitutedphenyl)piperidines |
| 04/28/2005 | US20050090517 Pharmaceutical combinations of cox-2 inhibitors and opiates |
| 04/28/2005 | US20050090513 Compounds specific to adenosine a1 and a3 receptors and uses thereof |
| 04/28/2005 | US20050090503 5-HT receptor ligands and uses thereof |
| 04/28/2005 | US20050090496 Sulphonyl compounds with 5-ht6 receptor affinity |
| 04/28/2005 | US20050090494 Such as N-[2-(3-{[1-(3,4-dichlorobenzylpiperidinyl]aminohydroxypropoxy)phenyl]acetamide; antiinflammatory agents, antiarthritic agents; chronic obstructive pulmonary disease, asthma, multiple sclerosis |
| 04/28/2005 | US20050090491 2'-Methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 04/28/2005 | US20050090490 3-Substituted-4-pyrimidone derivatives |
| 04/28/2005 | US20050090488 Drug combination for the treatment of depression and related disorders comprising mirtazapine |
| 04/28/2005 | US20050090485 7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders |
| 04/28/2005 | US20050090483 Purine derivatives as kinase inhibitors |
| 04/28/2005 | US20050090457 Method of treating mammals with genistein and/or genistein analogues |
| 04/28/2005 | US20050090449 treating neurodegenerative diseases by administering drugs that inhibit beta-secretase-mediated cleavage of amyloid precursor proteins |
| 04/28/2005 | US20050090441 inducing prolonged in vivo gene expression in mammal by contacting nonmuscular tissue with a nucleic acid, a histone, and an amphipathic compound; animal models: |
| 04/28/2005 | US20050090439 Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases |
| 04/28/2005 | US20050090431 Water soluble prodrugs of hindered alcohols |
| 04/28/2005 | US20050090000 Novel human 7TM protein and polynucleotides encoding the same |
| 04/28/2005 | US20050089984 Having a specific amino acid sequence, especially fused to a heterologous polypeptide; induces apoptosis |
| 04/28/2005 | US20050089960 Biosynthesis; immunoglobulin signal peptides; fusion proteins; for delivery to the central nervous system and eye by gene therapy; host cells |
| 04/28/2005 | US20050089945 Abeta 42 lowering agents |
| 04/28/2005 | US20050089938 For treatment of epilepsy, hypertension, angina pectoris, cerebral ischaemia, Parkinson's disease, insulin-dependent diabetes, and/or Lambert-Eaton myasthenic syndrome |
| 04/28/2005 | US20050089933 Compositions and methods for surrogate antibody modulation of an immune response and transport |
| 04/28/2005 | US20050089919 In vitro method of measuring the expression level of the human gene for early lymphocyte activation antigen CD69 exon1 (CD69) in the biological sample and providing a diagnosis and an increased susceptibility if the expression level is increased and vice versa; accurate and safe intervention |
| 04/28/2005 | US20050089911 87 human secreted proteins |
| 04/28/2005 | US20050089887 Novel human ion channel proteins |
| 04/28/2005 | US20050089866 Identifying modulators for the treatment and prevention of diabetes, pain, obesity, nervous system, inflammatory, cell proliferative and liver disorders |
| 04/28/2005 | US20050089855 Expression vector comprising nucleotide sequences coding glycine transport protein for use in identifying modulator for treatment and prevention of nervous system and psychiatric disorders |
| 04/28/2005 | US20050089574 Overcoating drug; sustained release; cardiovascular disorders; mixture of acrylic polymer and vinyl acetate polymer |
| 04/28/2005 | US20050089559 Flupirtine in combination with tolperisone or its analogs, such as eperisone or silperisone; pains which are accompanied by an increase in muscle tone such as neuralgia |
| 04/28/2005 | US20050089524 Compositions and compounds for use as molecular adjuvant for a nicotine vaccine |
| 04/28/2005 | US20050089510 Immunization against plaque forming diseases such as cardiovascular disorders with vaccines for disaggregation |
| 04/28/2005 | US20050089506 Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby |
| 04/28/2005 | US20050089495 Transdermal transport of compounds |
| 04/28/2005 | US20050089479 Delivery of sedative-hypnotics through an inhalation route |
| 04/28/2005 | US20050087198 Method for systemic drug delivery through the nail |
| 04/28/2005 | DE202004018534U1 Herbal composition for side-effect free treatment of depression, comprising herbs or herbal extracts for promoting blood flow and reducing coagulated blood levels, calming, sedation and flow of Qi |
| 04/28/2005 | CA2543447A1 Antibody and use of the same |
| 04/28/2005 | CA2542925A1 Derivatives of n-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics |
| 04/28/2005 | CA2542765A1 Method of inhibiting secretase activity |
| 04/28/2005 | CA2542761A1 Analgesia method |
| 04/28/2005 | CA2542727A1 Derivatives of n-[phenyl(pyrrolidine-2-yl)methyl]benzamide and n-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics |
| 04/28/2005 | CA2542504A1 Lipids containing omega-3 and omega-6 fatty acids |
| 04/28/2005 | CA2542395A1 Treatment of arthritic conditions, chronic inflammation or pain |
| 04/28/2005 | CA2542373A1 Derivatives of n-phenyl(piperidine-2-yl)methyl benzamide, preparation method thereof and applications of same in therapeutics |
| 04/28/2005 | CA2542370A1 Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics |
| 04/28/2005 | CA2542290A1 Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof |
| 04/28/2005 | CA2540195A1 Amphiphilic [5:1]- and [3:3]- hexakisadducts of fullerenes |
| 04/28/2005 | CA2539811A1 Azabicycyclic compounds for relieving pain and treating central nervous system disorders |
| 04/28/2005 | CA2539632A1 Amide or thioamide derivatives and their use in the treatment of pain |
| 04/27/2005 | EP1526382A1 Screening method for different indications using BNPI and/or DNPI |
| 04/27/2005 | EP1526141A2 MHC complexes and uses thereof |
| 04/27/2005 | EP1526136A1 Polymorphs of zaleplon and methods for the preparation thereof |
| 04/27/2005 | EP1526134A2 Triazolyl tropane derivatives as ccr5 modulators |
| 04/27/2005 | EP1526132A2 Substituted oxazolidinone derivatives and their use as factor xa inhibitors |
| 04/27/2005 | EP1526130A1 Substituted isoquinolines as ultra short acting neuromuscular blockers |
| 04/27/2005 | EP1525883A1 Ciclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 04/27/2005 | EP1525323A2 Pgc-beta, a novel pgc-1 homologue and uses therefor |
| 04/27/2005 | EP1525306A1 Three-dimensional structure of dipeptidyl peptidase iv |
| 04/27/2005 | EP1525205A2 Novel substituted pyrazolo( 1,5-a /i ]-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same |
| 04/27/2005 | EP1525204A1 Phenylalanine enamide derivatives |
| 04/27/2005 | EP1525203A1 4-amino-substituted pyrimidine derivatives |
| 04/27/2005 | EP1525202A1 Novel 2,5-disubstituted pyrimidine derivatives |
| 04/27/2005 | EP1525201A1 Bicyclic piperidine derivatives as antagonists of the ccr1 chemokine receptor |
| 04/27/2005 | EP1525200A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| 04/27/2005 | EP1525199A1 Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors |
| 04/27/2005 | EP1525198A2 Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof |
| 04/27/2005 | EP1525194A1 Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers |
| 04/27/2005 | EP1525193A2 Acylaminothiazole derivatives, preparation and therapeutic use thereof |
| 04/27/2005 | EP1525180A2 Arylethanolamine beta2-adrenoreceptor agonist compounds |
| 04/27/2005 | EP1524998A1 Stable pharmaceutical composition comprising erythropoietin |
| 04/27/2005 | EP1524997A1 Stable liquid parenteral parecoxib formulation |
| 04/27/2005 | EP1524994A1 Vaccine compositions containing amyloid beta1-6 antigen arrays |
| 04/27/2005 | EP1524989A2 Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
| 04/27/2005 | EP1524981A1 Sustained release formulations comprising lamotrigine |
| 04/27/2005 | EP1524980A1 Phenylalanine enamide derivatives containing a spiro[3.5]non-1-ene ring for use as integrin inhibitors |
| 04/27/2005 | EP1524975A1 Improved transdermal delivery system for the administration of rotigotine |
| 04/27/2005 | EP1524971A1 Improved transdermal delivery system |
| 04/27/2005 | EP1463723A4 Process for the preparation of simvastatin |
| 04/27/2005 | EP1456193B1 PREPARATION OF TRANS-FUSED 3,3a,8,12b-TETRAHYDRO-2 i H /i -DIBENZO 3,4:6,7]CYCLOHEPTA 1,2-b]FURAN DERIVATIVES |
| 04/27/2005 | EP1419150B1 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use |
| 04/27/2005 | EP1358320A4 68730 and 69112 protein kinase molecules and uses therefor |
| 04/27/2005 | EP1325010B1 Substituted 3.4-dihydro-pyrimido [1,2-a]pyrimidines and 3.4-dihydropyrazino [1,2-a]pyrimidines |
| 04/27/2005 | EP1261327B1 Adenosine receptor modulators |
| 04/27/2005 | EP1253932B1 Botulinum toxin pharmaceutical compositions |
| 04/27/2005 | EP1244662B1 Pyridazino quinoline derivative and method for the treatment of pain |
| 04/27/2005 | EP1143974B1 Pharmaceutical compositions for alleviating discomfort |
| 04/27/2005 | EP1015019B1 Compositions and methods of therapy for igf-i-responsive conditions |
| 04/27/2005 | EP0942733B1 Use of nk-1 receptor antagonists for treating cognitive disorders |
| 04/27/2005 | EP0850068B1 Lipid extract having anti-inflammatory activity |
| 04/27/2005 | CN1610738A Method of inducing differentiation of mesodermal stem cells, ES cells or immortalized cells into nervous system cells |
| 04/27/2005 | CN1610682A Polymorphs of zaleplon and methods for the preparation thereof |
| 04/27/2005 | CN1610675A Benzothiazole- and benzoxazole-4, 7-dione derivatives and their use as CDC25 phosphatase inhibitors |
| 04/27/2005 | CN1610674A Use of 2-amino-thiazoline derivatives as inhibitors of inducible NO-synthase |
| 04/27/2005 | CN1610671A Quinoline compounds with 5-HT-antagonistic properties for therapy |
| 04/27/2005 | CN1610670A 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists |
| 04/27/2005 | CN1610668A Substituted propane-1, 3-diamine derivatives and the pharmaceutical use |
| 04/27/2005 | CN1610664A 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists |